The First FDA Approved, Chinese Developed, PD-1 Inhibitor For Nasopharyngeal Carcinoma

On October 27th, 2023, the U.S. Food and Drug Administration (FDA) approved LOQTORZITM (toripalimab-tpzi), developed by Coherus BioSciences, Inc., and Shanghai Junshi Biosciences Co., Ltd., for two indications: 1) in combination with cisplatin and gemcitabine as treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and 2) as a single agent treatment in adults with recurrent, unresectable or metastatic NPC with disease progression on or after a platinum-containing…
By: Knobbe Martens